Clinical Trial

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Name: Gene Therapy for HER-Positive Cancer (SENTRY-HER2) — clinical trial record (NCT07192432)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SENTRY-HER2

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.

Protocol Amendment History 1 change

notable Trial sites expanded: 6 -> 10 locations 2026-06-25

Trial Details

NCT Number	NCT07192432
Lead Sponsor	Vironexis Biotherapeutics Inc.
Conditions	HER2 Expressing Solid Tumors
Enrollment	27 participants
Start Date	2025-11-18
Primary Completion	2033-09 (estimated)
Study Completion	2033-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-28